“I think in specialized cases, especially for patients [who] need focal therapy or want focal therapy, or [for whom] you're really trying to minimize any nerve damage or urethral damage…these are excellent therapies,” says Jennifer Linehan, MD.
In this video, Jennifer Linehan, MD, discusses what advancements she foresees in minimally invasive and robotic technologies and how they should be applied to the urologic oncology patient population. Linehan is an associate professor of urology and urologic oncology at the John Wayne Cancer Institute in Santa Monica, California.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.